VNLG-152R and its deuterated analogs potently inhibit/repress triple/quadruple negative breast cancer of diverse racial origins in vitro and in vivo by upregulating E3 Ligase Synoviolin 1 (SYVN1) and inducing proteasomal degradation of MNK1/2 is a research paper published in Frontiers in Oncology (2023). On theSindex it has a DataRank of 0.241. It has been cited 4 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.241
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NCI NIH HHS
Grant: R01 CA224696
National Institutes of Health
Grant: 1R01CA224696-01A1
Development of Next Generation Galeterone Analogs for Prostate Cancer Therapy
FWCI
0.37
Citation Percentile
0.5%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals